ZYBERNO
Stock Report
Updated Aug 30, 2026

Dianthus Therapeutics, Inc. (DNTH)

Healthcare • NASDAQ

$105.84

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
39.0/100
WEAK BUSINESS
Dianthus Therapeutics, Inc. (DNTH) scores 39/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-22.5%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-1,178.4%)
Return on Capital (Capital Efficiency):CRITICAL (-15.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Dianthus Therapeutics, Inc. (DNTH) stock report — Zyberno Score 39/100 (WEAK BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, DNTH generated -$130.36M in Owner Earnings. Capital was deployed as follows: $199.00K invested in capital expenditures. Reinvestment rate: -0.1%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:105.84
Market Cap:$5.93B

Valuation Multiples (3)

P/B Ratio:5.06x
P/S Ratio:320.77x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$5.82B

Price Action & Momentum (3)

Momentum Percentile:99 / 100
% of 52-Week High:89.8%
B. Profitability Assessment

Return Metrics (5)

ROA:-21.5%
Reinvestment Rate:-0.1%
Fundamental Growth Rate (g):0.0%

Margin Analysis (3)

Operating Margin Ttm:-1,178.4%
Net Margin Ttm:-1,039.9%
Ebitda Margin:-1,177.7%

TTM Performance (2)

Operating Margin Ttm:-1,178.4%
Net Margin Ttm:-1,039.9%

Yield Metrics (2)

Earnings Yield:-$4.02
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:15.2%
Latest Earnings Filed:2026-08-04

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):83.6%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:26.10x
Quick Ratio:26.10x
Cash Ratio:3.21x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:863,148,000.00
Cash And Cash Equivalents:110,549,000.00
Long Term Debt:$913.00K
Net Debt:-$109.26M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $18.49M
Linear Growth: 83.6%
📊 Click to view full DNTH Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$217.84M

Bottom Line Performance (3)

-$192.25M
Income Before Tax:$0.00
Ebitda Ttm:-217,721,000.00

Operating Expenses (5)

Operating Expenses:219,748,000.00
R And D Expense:175,598,000.00
Sga Expense:44,150,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:1,521.4%
Sga To Revenue Percentage:382.5%
Ebitda Margin:-1,177.7%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$1.21B
Current Assets:$897.54M
Ppe Net:418,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:41,246,000.00
Current Liabilities:34,389,000.00
Long Term Debt:$913.00K
Short Term Debt:$374.00K

Equity & Capital (3)

Equity:$1.17B
Retained Earnings:-$427.78M
Common Stock:150,000,000.00

Working Capital Items (3)

Accounts Receivable:106,000.00
Inventory:0.00
Accounts Payable:26,101,000.00

Special Items (2)

Contract Liabilities:1,524,000.00
Stock Based Compensation:11,898,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$130.29M-$130.49M

Investment Activities (2)

Investing Cash Flow:-$133.97M
Capital Expenditures Ttm:199,000.00

Financing Activities (3)

Financing Cash Flow:$739.41M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:120,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:123,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-4.25
-$4.25
Earnings Per Share Ttm:-$3.43

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.33
Operating Cash Flow Per Share:-$2.30

Book Value & Capital (2)

Book Value Per Share:$20.92
Cash Per Share:1.97

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.02x
Working Capital Turnover Ttm:0.02x

Receivables Management (2)

Receivables Turnover Ttm:174.41x
Days Sales Outstanding Ttm:2.09

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:515.33
Cash Conversion Cycle:-1,512.23
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$130.36M

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.1%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):83.6%

Other Growth Rates (1)

Book Value Growth Rate (Linear):70.1%
C. Company Profile & Context

Corporate Information (6)

Symbol:DNTH
Company Name:Dianthus Therapeutics, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:high
Volume Category:N/A

Share Structure (3)

Shares Outstanding:56.03M
Shares Outstanding Basic:56.03M
Shares Outstanding Diluted:56.03M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-30 08:29:36 UTC
Data Timestamp:2026-08-30T08:29:36.723990
Scroll to Top